A phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of XL844 administered orally to subjects with chronic lymphocytic leukaemia
Phase of Trial: Phase I
Latest Information Update: 01 Apr 2007
At a glance
- Drugs XL 844 (Primary)
- Indications Chronic lymphocytic leukaemia; Lymphoma
- Focus Adverse reactions
- 13 Nov 2005 New trial record.